

RECEIVED
CENTRAL FAX CENTER

SEP 28 2006

JENKINS, WILSON & TAYLOR, P.A.**PATENT ATTORNEYS**

SUITE 1400 UNIVERSITY TOWER
3100 TOWER BOULEVARD
DURHAM, NORTH CAROLINA 27707
TELEPHONE: (919) 493-8000
FACSIMILE: (919) 419-0383

WEBSITE: WWW.JENKINSWILSONTAYLOR.COM

DATE: September 28, 2006

TO: U.S. Patent and Trademark Office
ATTN: Examiner Stephen Kapushoc

FAX NO.: (571) 273-8300

FROM: Arles A. Taylor, Jr. (omb)

RE: Serial No. 10/806,899; Atty. Docket No. 1386/19

NUMBER OF PAGES TO FOLLOW: 6

If transmission is poor, or if you do not receive all pages, please
call (919) 493-8000 as soon as possible.

COMMENTS:**Attachments:**

1. Transmittal Letter (1 page); and
2. A Response to Restriction/Election Requirement (5 pages).

The information contained in this facsimile message is **ATTORNEY PRIVILEGED AND CONFIDENTIAL INFORMATION** intended only for the use of the individual or entity named as recipient. If the reader is not the intended recipient, be hereby notified that any dissemination, distribution or copy of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by phone and return the original message to us at the address shown above via the U.S. Postal Service. Thank you.

RECEIVED
CENTRAL FAX CENTER

SEP 28 2006

JENKINS
WILSON
TAYLOR
& HUNT

patent attorneys

September 28, 2006

I hereby certify that this correspondence is being transmitted via
facsimile to the Commissioner for Patents, P.O. Box 1450,
Alexandria, VA 22313-1450 on September 28, 2006

Oksana Buynitsky
Oksana Buynitsky
Date of Signature

September 28, 2006

RICHARD E. JENKINS

JEFFREY L. WILSON

ARLES A. TAYLOR, JR.

GREGORY A. HUNT

BENTLEY J. OLIVE

CHRIS PERKINS, PH.D.

JAMES DALY IV, PH.D.

PASHLEY DARDEN

DAVID M. SIGMON

WESLEY A. SHEFFIELD

PATENT AGENT
JAY KLINCKTECHNICAL SPECIALIST
AMY ODENBAUGH, PH.D.

LICENSED ONLY IN CA

LICENSED ONLY IN KY

LICENSED ONLY IN SC

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Re: U.S. Patent Application Serial No. 10/806,899 for
A DIAGNOSTIC METHOD FOR EPILEPSY
Our File No. 1386/19

Sir:

Please find enclosed in connection with the subject U.S. patent application the
following documents:

1. A Response to Restriction/Election Requirement (5 pages).

The Commissioner is hereby authorized to charge any fees associated with the
filing of this correspondence to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS, WILSON, TAYLOR & HUNT, P.A.

Arles A. Taylor, Jr.
Arles A. Taylor, Jr.
Registration No. 39,395
Customer No.: 25297


AAT/AD/omb

Enclosures

RECEIVED
CENTRAL FAX CENTER

SEP 28 2006

I hereby certify that this paper is being facsimile transmitted
to the United States Patent and Trademark Office on the date
shown below.


Oksana Buynitzky
Date of Signature September 28, 2006

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Petrou et al.

Group Art Unit: 1634

Serial No.: 10/806,899

Examiner: Kapushoc, Stephen Thomas

Filed: March 23, 2004

Docket No.: 1386/19

Confirmation No.: 2461

For: A DIAGNOSTIC METHOD FOR EPILEPSY

RESPONSE TO RESTRICTION/ELECTION REQUIREMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This is responsive to the Restriction/Election Requirement dated August 28,
2006, having a 1-month term for Response that expires on September 28, 2006.
Favorable consideration is respectfully requested in view of the following Election and
Remarks.

RECEIVED
CENTRAL FAX CENTER

Application Serial No.: 10/806,899

SEP 28 2006

RESTRICTION PRESENTED

The claims have been restricted into the following groups of inventions:

<u>Groups</u>	<u>Claims</u>	<u>Subject Matter</u>
I	7, 8, 11-17, 20, and 21	Nucleic acid based methods for the diagnosis of SMEI by detecting alteration in the SCN1A gene.
II	18 and 19	Amino acid based methods for the diagnosis of SMEI by detecting alteration in the SCN1A protein.
III	22	A method of determining a treatment for a SMEI patient
IV	23	A method of determining the likelihood of adverse results from treatments of a SMEI patient.

APPLICANTS' ELECTION

Applicants hereby elect with traverse the invention of Group I, claims 7, 8, 11-17, 20 and 21, pertaining to nucleic acid based methods for the diagnosis of SMEI by detecting alteration in the SCN1A gene, for prosecution at this time. Applicants also elect the following alteration from Table 3, page 46 of the subject application: the missense mutation corresponding to the c251A→G nucleotide change. Applicants submit that linking claims 1-6, 9 and 10 should be joined and examined with the claims of Group I.